Trastuzumab Deruxtecan 100MG Injection is an advanced HER2-targeted antibody-drug conjugate (ADC) used for selected HER2-related cancers. The 100MG presentation is supplied for intravenous administration and must be used under qualified oncology supervision. Current regulatory information includes multiple approved indications for trastuzumab deruxtecan, with eligibility depending on cancer type and HER2 status.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter supporting eligible hospitals, oncology centers, pharma distributors and authorized healthcare buyers with international pharmaceutical sourcing and export coordination.
Global Supply of Trastuzumab Deruxtecan 100MG
Cordium Pharmaceuticals supports inquiries for eligible buyers in:
- Morocco
- Kenya
- Singapore
- Australia
- Germany
- France
- Canada
- Saudi Arabia
Product availability, import permissions, registration and prescription requirements vary by country.
Uses of Trastuzumab Deruxtecan
Depending on the applicable approval, trastuzumab deruxtecan may be used for selected:
- HER2-positive breast cancer
- HER2-low and HER2-ultralow breast cancer
- HER2-mutant non-small cell lung cancer
- HER2-positive gastric or gastroesophageal junction cancer
- Certain HER2-positive solid tumors
The FDA has also expanded approved uses in 2026 to include certain HER2-positive early-stage breast cancer settings.
Dosage & Administration
100MG is the vial strength and is not necessarily the patient's individual dose.
For several approved indications, the recommended dosage is 5.4 mg/kg by intravenous infusion every 3 weeks. Certain gastric cancer indications use a different weight-based dose.
The medicine must be prepared and administered by qualified healthcare professionals.
Key Benefits
- HER2-targeted oncology therapy
- Antibody-drug conjugate technology
- Used for multiple approved HER2-related cancer indications
- Treatment option for appropriately selected patients
- Suitable for hospital and specialist oncology procurement
Important Safety Information
Possible adverse effects include nausea, vomiting, fatigue, decreased appetite, low blood-cell counts, anemia and gastrointestinal symptoms.
Trastuzumab deruxtecan carries important warnings for interstitial lung disease/pneumonitis and embryo-fetal toxicity. Patients should promptly report cough, shortness of breath, fever or other new respiratory symptoms.
Why Choose Cordium Pharma?
India-Based Pharmaceutical Exporter
Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical export support from India for eligible international buyers.
Hospital & Distributor Support
We support procurement inquiries from hospitals, oncology centers, pharmaceutical distributors and authorized healthcare organizations.
International Order Coordination
We assist eligible buyers with order coordination, commercial documentation and international shipment arrangements.
Export Documentation Support
Relevant commercial and export documentation can be coordinated according to the order and destination requirements.
Professional Pharmaceutical Logistics
Shipment arrangements can be coordinated according to applicable product handling and destination requirements.
Multiple International Markets
Cordium Pharma supports pharmaceutical export inquiries for Morocco, Kenya, Singapore, Australia, Germany, France, Canada and Saudi Arabia, subject to local regulations.
Personal Import of Trastuzumab Deruxtecan
Patients seeking trastuzumab deruxtecan for personal treatment should first consult their oncologist and verify the destination country's import requirements. A prescription, medical documentation or import authorization may be required.
Because this is a specialized injectable oncology medicine, personal import should never be treated as self-medication and administration should take place under professional medical supervision.
FAQs
What is Trastuzumab Deruxtecan 100MG Injection?
It is a HER2-targeted antibody-drug conjugate used for selected HER2-related cancers.
Who can purchase Trastuzumab Deruxtecan?
Eligible hospitals, oncology centers, pharmaceutical distributors and authorized healthcare buyers can contact suppliers, subject to local regulations.
Is 100MG the standard patient dose?
No. 100MG refers to the vial presentation. The prescribed dose depends on the patient's diagnosis, body weight and applicable treatment indication.
How often is Trastuzumab Deruxtecan given?
Several approved indications use intravenous treatment once every three weeks, although the dose varies according to the indication.
Can patients administer it themselves?
No. It is an intravenous oncology medicine that should be prepared and administered by trained healthcare professionals.
Does HER2 testing matter?
Yes. Appropriate HER2 testing or mutation assessment is required for indications based on HER2 status.
Does Cordium Pharma export internationally?
Cordium Pharmaceuticals Pvt Ltd supports eligible pharmaceutical export inquiries from India for international markets, subject to destination-country regulations.
Which countries are covered?
Cordium Pharma supports inquiries for Morocco, Kenya, Singapore, Australia, Germany, France, Canada and Saudi Arabia.
Conclusion
Trastuzumab Deruxtecan 100MG Injection is an important targeted oncology medicine for selected HER2-related cancers. Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical export and supply coordination from India for eligible hospitals, pharma distributors and authorized healthcare buyers across Morocco, Kenya, Singapore, Australia, Germany, France, Canada and Saudi Arabia.
For product availability, specifications, documentation and export inquiries, contact Cordium Pharmaceuticals Pvt Ltd.
Medical Disclaimer: This content is for informational and pharmaceutical procurement purposes only. Trastuzumab deruxtecan is a prescription oncology medicine and should be used only under qualified medical supervision.